Skip to main content
. 2020 Jan 15;128(1):017002. doi: 10.1289/EHP5221

Figure 2.

Figures 2A and 2B are bar graphs plotting relative fold change in TFF1 expression (ranging from 0 to 20) and gamma H 2 A X intensity per nucleus (ranging from 0 to 250) (y-axis) across control, E subscript 2 (10 nanomolar), BP-3 (5 micromolar), PP (5 micromolar) for negative and positive fulvestrant (x-axis).

TFF1 expression and γ-H2AX intensity in T47D cells treated with 17β-estradiol (E2), benzophenone-3 (BP-3), or propylparaben (PP) for 24h with or without the ER antagonist fulvestrant. (A) Inhibition of TFF1 expression following treatment of 10  nM E2, 5μM BP-3, and 5μM PP when cotreated with fulvestrant (ICI 182 780, 1μM) compared with 10  nM E2, 5μM BP-3, and 5μM PP treatments without fulvestrant. (B) Quantification of nuclear γ-H2AX following cotreatment of fulvestrant (1μM) with E2 (10  nM), BP-3 (5μM), or PP (5μM) compared with E2 (10  nM), BP-3 (5μM), or PP (5μM) without fulvestrant treatment, respectively. ***p<0.0001 compared control to xenoestrogens treatment and ###p<0.001 compared with negative fulvestrant and with positive fulvestrant using multiple comparison for 2-way ANOVA. n=3 biological replicates. All graphs show mean ± SEM.